생분해성 관상동맥 스텐트 시장 : 재료별, 용도별, 최종사용자별, 유통 채널별 - 세계 예측(2026-2032년)

The Biodegradable Coronary Stents Market was valued at USD 1.41 billion in 2025 and is projected to grow to USD 1.52 billion in 2026, with a CAGR of 6.79%, reaching USD 2.24 billion by 2032.

Emerging clinical imperatives and technological maturation reshaping biodegradable coronary stents toward patient-centric vascular healing and procedural efficiency

Biodegradable coronary stents represent an inflection point in interventional cardiology, combining advances in materials science with evolving clinical priorities for vascular restoration and long-term vessel integrity. The contemporary conversation centers on the capacity of resorbable devices to reduce late-stage complications associated with permanent metallic scaffolds while enabling secondary interventions and physiological vessel responses. Clinicians and hospital systems are increasingly weighing the trade-offs between immediate procedural efficacy and long-term vessel healing, prompting device developers to refine strut designs, drug-elution profiles, and resorption kinetics.

As regulatory pathways have become more defined for bioresorbable technologies, stakeholder attention is shifting toward clinical evidence that demonstrates durable outcomes across diverse patient cohorts and lesion types. Parallel improvements in imaging, lesion preparation techniques, and adjunctive pharmacotherapy are reinforcing the practicality of these devices in routine practice. Consequently, procurement and clinical leaders are seeking deeper insight into comparative performance, supply chain resilience, and the operational implications of adopting biodegradable stents within catheterization lab workflows. The following analysis synthesizes these dynamics to inform strategic planning across product development, commercialization, and clinical adoption programs.

Converging forces of materials innovation, regulatory clarity, and value-based care models accelerating structural shifts in the biodegradable stent landscape

The landscape for biodegradable coronary stents is undergoing transformative shifts driven by converging technological, regulatory, and commercial forces. Material innovation is advancing beyond early polymer concepts to include alternative resorbable metals and hybrid constructs that aim to balance radial strength with predictable degradation. These technical refinements, coupled with iterative improvements in drug-eluting coatings and delivery systems, are enhancing operator confidence and expanding the clinical scenarios in which resorbable scaffolds are considered viable.

Concurrently, healthcare payment models and hospital procurement strategies are placing greater emphasis on long-term patient outcomes and total cost of care. Value-based care imperatives are prompting health systems to favor devices that demonstrably reduce downstream interventions and rehospitalizations. Regulatory authorities have also clarified expectations for safety and post-market surveillance, which is enabling more efficient pathways to reimbursement and formulary inclusion. In response, manufacturers are prioritizing real-world evidence generation, partnerships with clinical centers of excellence, and lifecycle plans that address post-market data collection and iterative device improvements.

These combined shifts are creating a more competitive environment where clinical differentiation, supply reliability, and robust evidence packages determine the pace and scale of adoption. Organizations that align R&D priorities with payer requirements and clinician needs are positioned to convert technological promise into durable clinical and commercial outcomes.

Cumulative trade policy shifts including United States tariff changes in 2025 prompting supply chain realignment, cost pass-through and strategic sourcing responses

United States tariff actions enacted in 2025 have introduced a new dimension of commercial complexity for companies operating in the biodegradable coronary stents ecosystem, prompting immediate reassessments of procurement, manufacturing, and inventory strategies. Tariff adjustments on raw materials, finished medical devices, or associated components can increase landed costs and compress margins, which in turn influences pricing strategies and contractual negotiations with health systems and distributors. Suppliers and manufacturers are responding by reviewing sourcing footprints, seeking tariff advisory services, and exploring potential tariff mitigation mechanisms available under trade agreements and customs classifications.

The ripple effects extend beyond input costs. Clinical trial supply logistics, capital equipment acquisitions for manufacturing, and cross-border after-sales support are all subject to the operational frictions introduced by tariff regimes. In practice, device makers have accelerated supplier diversification, prioritized local manufacturing or assembly where feasible, and engaged more closely with distributor partners to preserve competitive tendering positions. Purchasers are likewise adapting contracting approaches to include clauses that address tariff-related cost adjustments and to evaluate total landed cost rather than purchase price alone.

Moreover, tariff changes interact with reimbursement and procurement policies, influencing how hospitals and ambulatory centers evaluate vendor bids and long-term device partnerships. Effective responses require coordinated action across regulatory affairs, supply chain, and commercial teams to ensure continuity of supply, transparency in pricing, and alignment with clinician preferences. The net result is a market environment where agility in sourcing and clarity in contractual terms are as important as clinical differentiation.

Segmentation-driven competitiveness highlighting materials selection, clinical indications, care settings and distribution pathways as determinants of adoption and procurement

Segmentation insights reveal how material science, clinical indication, care setting, and distribution pathways collectively shape adoption dynamics for resorbable coronary devices. Material-based differentiation remains foundational: iron-based constructs offer alternative degradation profiles and mechanical behaviors, magnesium-based scaffolds bring a distinct balance of strength and resorption, and polymer platforms-further delineated into PDLLA and PLLA chemistries-present different handling characteristics and drug-elution compatibility. These material choices directly influence procedural workflow, imaging compatibility, and post-procedural monitoring requirements.

Clinical applications bifurcate into patients presenting with acute coronary syndrome and those managed for stable angina, each cohort raising different evidence priorities and risk tolerances. Devices that demonstrate rapid endothelialization and predictably controlled resorption are more likely to be favored in acute settings where thrombosis risk and lesion complexity are heightened, whereas long-term vessel integrity and reduced late complications are paramount considerations in elective stable angina interventions. End-user segmentation further modulates procurement and utilization patterns: ambulatory surgical centers and hospitals display distinct purchasing cycles, inventory management capabilities, and preferences for vendor support. Within ambulatory settings, the contrasts between hospital-owned ambulatory surgical centers and independent facilities affect contracting leverage and logistics, while within hospital systems, cardiac centers and multi-specialty hospitals exhibit different decision-making processes tied to volume, specialty focus, and capital planning.

Distribution channels also play a pivotal role: direct tender relationships typically support larger institutional contracts and tighter price negotiation, whereas third-party distributors provide broader geographic reach and inventory flexibility for smaller or decentralized buyer groups. Taken together, these segmentation axes inform product positioning, clinical evidence strategies, and commercial models that manufacturers must adopt to effectively address heterogeneous customer needs.

Regional dynamics revealing divergent adoption patterns across the Americas, Europe Middle East and Africa, and Asia-Pacific driven by infrastructure, regulation and reimbursement

Regional dynamics exert powerful influence over the trajectory of biodegradable coronary stent adoption, reflecting differences in healthcare infrastructure, regulatory frameworks, and reimbursement environments. In the Americas, clinician familiarity with interventional cardiology innovations and the structure of hospital networks shape rapid technology transfer, but payer scrutiny and procurement protocols require clear demonstration of clinical and economic value. Across Europe, the Middle East and Africa, divergent regulatory regimes and variable reimbursement pathways create a mosaic of adoption timing, with leading cardiac centers often acting as early adopters and diffusion progressing as national health systems and payers align coverage policies.

Asia-Pacific presents a distinct landscape dominated by manufacturing ecosystems, government-led health initiatives, and rapidly expanding procedural volumes in urban centers. Local production capabilities and negotiated pricing frameworks can accelerate availability, while differences in clinical practice patterns and lesion presentations influence device selection. Transitional phrases such as moreover and consequently highlight how cross-regional partnerships, technology transfer arrangements, and regional clinical trials are shaping localized strategies. Manufacturers seeking global traction must therefore craft differentiated approaches that respect regional regulatory timelines, reimbursement considerations, and the operational realities of supply and distribution within each geography.

Competitive profiles and strategic moves by manufacturers, contract partners and distributors influencing technology diffusion and clinical partnerships across care ecosystems

Competitive dynamics are increasingly defined by the depth of clinical partnerships, the agility of manufacturing and distribution networks, and the robustness of post-market evidence programs. Leading device developers are investing in head-to-head clinical collaborations with academic cardiac centers to demonstrate procedural performance and long-term vessel outcomes, while also expanding contract manufacturing partnerships to ensure capacity and component security. Strategic alliances with distributors and integrated delivery networks enable broader reach into ambulatory surgical centers and multi-hospital systems, while dedicated service models-comprising physician training, procedural proctoring, and after-sales clinical support-bolster uptake among high-volume operators.

Companies that prioritize transparent regulatory engagement and active post-market surveillance are better positioned to address clinician concerns about durability and safety. At the same time, contract terms with health systems emphasize service-level agreements, outcome reporting commitments, and supply continuity guarantees. The competitive field is also seeing differentiated plays in adjacent value propositions such as integrated procedural kits, imaging-matched devices, and evidence-backed training curricula. Collectively, these strategic choices establish barriers to entry and create pathways for scale that prioritize clinical trust, operational reliability, and alignment with system-level performance metrics.

Actionable strategies for industry leaders to strengthen resilience, accelerate clinical adoption, and optimize commercial models amid evolving regulatory and trade environments

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture clinical mindshare in the biodegradable stent domain. First, prioritize clinical evidence generation that aligns with payer and clinician decision criteria, emphasizing real-world outcomes, safety endpoints, and comparative effectiveness across acute coronary syndrome and stable angina cohorts. Second, develop flexible manufacturing footprints and supplier diversification plans that mitigate tariff and trade risks while preserving cost competitiveness and on-time delivery reliability.

Third, tailor commercial models to the needs of distinct end users by offering differentiated support packages for hospital-owned ambulatory surgical centers, independent facilities, cardiac centers, and multi-specialty hospitals; such customization should encompass inventory solutions, clinician training, and outcome reporting tools. Fourth, refine distribution strategies to balance direct tender opportunities with selective third-party distributor partnerships that provide geographic reach without diluting service standards. Fifth, engage proactively with regional regulatory and reimbursement stakeholders to shorten time-to-formulary and to ensure that post-market surveillance commitments are integrated into lifecycle planning. Finally, embed scenario planning for trade policy shifts into corporate governance processes to enable rapid, cross-functional responses when tariff landscapes change. Together, these measures create a coherent playbook for navigating clinical, commercial, and policy complexity.

Robust research methodology integrating primary clinical stakeholder interviews, supply chain mapping and triangulated secondary intelligence to ensure analytical rigor

This analysis is grounded in a multi-method research methodology designed to ensure analytical rigor and practical relevance. Primary qualitative interviews were conducted with interventional cardiologists, procurement officers, regulatory specialists, and distribution partners to capture first-hand perspectives on clinical performance, purchasing drivers, and operational barriers. These conversations were supplemented by supply chain mapping exercises that traced component sourcing, manufacturing dependencies, and distribution pathways to identify potential points of fragility and opportunities for mitigation.

Secondary intelligence was triangulated from regulatory guidance documents, clinical trial registries, peer-reviewed clinical literature, and publicly available procurement policies to validate themes emerging from primary research. Data synthesis emphasized cross-validation, with iterative feedback loops to refine hypotheses and reconcile divergent viewpoints. Analytical frameworks included scenario analysis for trade policy impacts, segmentation-based prioritization for commercial planning, and capability gap assessments to inform recommended strategic actions. Together, these methods produced a nuanced, action-oriented body of insight tailored for device manufacturers, clinical leaders, and purchasing organizations.

Conclusive synthesis underscoring clinical, commercial and policy priorities that will determine the trajectory of biodegradable coronary stents adoption and innovation

The conclusion synthesizes the core findings and clarifies the immediate implications for stakeholders across the biodegradable coronary stents ecosystem. Technological progress in materials and device design, coupled with tighter regulatory expectations and evolving payment models, is elevating the importance of real-world evidence and supply chain resilience. Tariff developments in 2025 add a pragmatic layer of commercial risk that requires integrated responses from procurement, manufacturing, and commercial teams. Adoption trajectories will be shaped not only by device performance but also by the ability of manufacturers to demonstrate predictable supply, post-market vigilance, and alignment with institutional priorities.

Forward-looking organizations will integrate clinical, operational, and commercial strategies to convert innovation into sustained clinical adoption. This requires disciplined evidence programs, flexible sourcing and manufacturing arrangements, and commercial offerings tailored to the needs of different care settings and regional markets. Ultimately, the successful diffusion of biodegradable coronary stents will depend on how well stakeholders manage the intersection of clinical value, operational execution, and policy-driven commercial constraints.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Porter's Five Forces Analysis
• 4.4. PESTLE Analysis
• 4.5. Market Outlook
  • 4.5.1. Near-Term Market Outlook (0-2 Years)
  • 4.5.2. Medium-Term Market Outlook (3-5 Years)
  • 4.5.3. Long-Term Market Outlook (5-10 Years)
• 4.6. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biodegradable Coronary Stents Market, by Material

• 8.1. Iron
• 8.2. Magnesium
• 8.3. Polymer
  • 8.3.1. Pdlla
  • 8.3.2. Plla

9. Biodegradable Coronary Stents Market, by Application

• 9.1. Acute Coronary Syndrome
• 9.2. Stable Angina

10. Biodegradable Coronary Stents Market, by End User

• 10.1. Ambulatory Surgical Centers
  • 10.1.1. Hospital-Owned Ambulatory Surgical Centers
  • 10.1.2. Independent Ambulatory Surgical Centers
• 10.2. Hospitals
  • 10.2.1. Cardiac Centers
  • 10.2.2. Multi-Specialty Hospitals

11. Biodegradable Coronary Stents Market, by Distribution Channel

• 11.1. Direct Tender
• 11.2. Third Party Distributor

12. Biodegradable Coronary Stents Market, by Region

• 12.1. Americas
  • 12.1.1. North America
  • 12.1.2. Latin America
• 12.2. Europe, Middle East & Africa
  • 12.2.1. Europe
  • 12.2.2. Middle East
  • 12.2.3. Africa
• 12.3. Asia-Pacific

13. Biodegradable Coronary Stents Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Biodegradable Coronary Stents Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. United States Biodegradable Coronary Stents Market

16. China Biodegradable Coronary Stents Market

17. Competitive Landscape

• 17.1. Market Concentration Analysis, 2025
  • 17.1.1. Concentration Ratio (CR)
  • 17.1.2. Herfindahl Hirschman Index (HHI)
• 17.2. Recent Developments & Impact Analysis, 2025
• 17.3. Product Portfolio Analysis, 2025
• 17.4. Benchmarking Analysis, 2025
• 17.5. Abbott Laboratories
• 17.6. Amaran Biotechnology Co., Ltd.
• 17.7. Amendia, Inc.
• 17.8. Arterial Remodeling Technologies, Inc.
• 17.9. Biomedical Structures, Inc.
• 17.10. Biotronik SE & Co. KG
• 17.11. Boston Scientific Corporation
• 17.12. Cook Medical LLC
• 17.13. Cordis Corporation
• 17.14. Elixir Medical Corporation
• 17.15. Endologix, Inc.
• 17.16. HeartFlow, Inc.
• 17.17. Hengrui Medicine Co., Ltd.
• 17.18. Inflow Dynamics Corp.
• 17.19. Johnson & Johnson Services, Inc.
• 17.20. Lepu Medical Technology (Beijing) Co., Ltd.
• 17.21. Meril Life Sciences Pvt. Ltd.
• 17.22. OrbusNeich Medical Company
• 17.23. Reva Medical, Inc.
• 17.24. Shanghai MicroPort Medical (Group) Co., Ltd.
• 17.25. Sino Medical Sciences Technology Inc.
• 17.26. Svelte Medical Systems Ltd.
• 17.27. Terumo Corporation
• 17.28. Translumina GmbH
• 17.29. Xeltis AG